Real World Evidence Conversations

Real World Evidence: From Data to Decisions

The pharmaceutical industry is undergoing a fundamental shift. Traditional randomized controlled trials (RCTs), while critical, often leave gaps in understanding how therapies perform in diverse, real-world settings. Real world evidence (RWE), drawn from real world data (RWD) such as electronic health records, patient registries, and claims databases, is increasingly shaping clinical, regulatory, and commercial decisions.

The FDA and other global regulators now actively consider RWE in drug approvals, label expansions, and post-market surveillance. For pharma and biotech companies, this means developing robust real world evidence strategies is a necessity for success.

To explore this evolving landscape, Navitas Life Sciences, in partnership with Healthcare Innovation Catalysts (HIC), is proud to present the first webcast in our new series:

Real World Conversations About Real World Evidence: FDA Insights and Real-World Registry Success

Why This Webcast Matters

The webcast is designed to answer some of the most pressing questions facing the industry today:

• How is the FDA integrating RWE into regulatory decisions?
• What makes patient registries successful in practice?
• How can sponsors ensure their RWE is regulatory-grade and submission-ready?
• What role do real world data companies and advanced analytics play in accelerating market access?

This session will combine regulatory perspectives, scientific rigor, and practical case experiences, offering a roadmap for pharma leaders who need actionable real world evidence solutions.

Meet the Experts

Dr. Yun Lu, PhD

SVP & Chief Science and Innovation Officer

Navitas Life Sciences

Dr. Benjamin C. Eloff, PhD

Head of Client Delivery & Quality

Healthcare Innovation Catalysts

Janel Shelton-DeMagnus

Director, Therapeutic Lead and Strategy

Navitas Life Sciences

These experts share perspectives on clinical trial design, biostatistics, patient registries, and RWE strategies.

HIC, a trusted partner in the life sciences space, optimizes clinical trial design, biostatistics, and real world evidence strategies to ensure regulatory compliance, data reliability, and efficient study execution, making them an ideal collaborator for this webcast.

Real World Evidence: Market Momentum

The importance of RWE is underscored by rapid market growth. According to Data Insights Market (2025), the global real world evidence solutions market is projected to exceed USD 1 billion by 2025, with a 12% CAGR through 2033.

This expansion is driven by:

• The adoption of digital health technologies like EHRs and wearables
• Regulatory bodies embracing RWE for approvals and surveillance
• Rising prevalence of chronic diseases

Navitas Life Sciences: Delivering Real World Evidence Solutions

As one of the leading real world evidence consulting partners, Navitas Life Sciences combines scientific rigor, operational excellence, and regulatory insight to deliver fit-for-purpose evidence solutions.

Our capabilities include:

• Patient registries designed for rare and common diseases
• Real world data pharma solutions with interoperable, analytics-ready datasets
• AI/ML analtics to forecast outcomes and detect patterns
• Submission-ready RWE support for FDA, EMA, and global regulators

By blending real world evidence consulting expertise with operational delivery, we help sponsors transform real world data into real world evidence strategies that withstand regulatory scrutiny and drive patient impact.

What You’ll Gain from the Webcast

This exclusive webcast will provide:

• FDA insights into how regulators view and use RWE
• Best practices for designing and sustaining patient registries
• Forward-looking strategies

For pharma leaders, medical affairs teams, and regulatory experts, this session offers a chance to hear directly from those shaping the future of real world evidence solutions.

Webcast Series: Real World Conversations about Real World Evidence

Part 1: FDA Insights and Real-World Registry Success

The demand for credible, actionable RWE has never been greater. Whether you are preparing regulatory submissions, designing patient registries, or exploring long-term real world data strategies, this webcast will equip you with the knowledge to succeed.

Hosted by

Watch the Webcast Now!

Real Evidence Solutions and Impact

This webcast marks the first in our Real World Conversations series, designed to provide pharma and biotech leaders with actionable insights into RWE, RWD, and patient registries.

By partnering with Navitas Life Sciences, sponsors gain not only the right data, but also the right insights, methodologies, and regulatory expertise to ensure their RWE truly makes an impact.

Stay tuned for the next session in the series, where we’ll continue to explore how evidence-driven innovation is transforming healthcare.

Don’t miss the opportunity to hear from Navitas Life Sciences and HIC experts in this important conversation. Watch the webcast today and discover how real world evidence solutions can shape the future of healthcare.

Learn more about our services and solutions by reaching out to us at This email address is being protected from spambots. You need JavaScript enabled to view it..